Skip to main content
Top
Published in: AIDS and Behavior 5/2017

01-05-2017 | Original Paper

Reaching Key Populations: PrEP Uptake in an Urban Health Care System in the Bronx, New York

Authors: Cedric H. Bien, Viraj V. Patel, Oni J. Blackstock, Uriel R. Felsen

Published in: AIDS and Behavior | Issue 5/2017

Login to get access

Abstract

Pre-exposure prophylaxis (PrEP) has been established as an effective HIV prevention tool, but real world studies are limited. To inform dissemination efforts, we sought to describe individuals prescribed PrEP in the largest health care system in the Bronx, New York, an urban region with a high burden of HIV. We used a clinical database and chart review to identify individuals prescribed PrEP between 2011 and 2015 (n = 108). A majority were Black and Hispanic, half were men who have sex with men, and nearly a third were cisgender women who have sex with men. Primary care settings were the most common site of PrEP prescription and PrEP prescription rates increased over time. Despite reaching a diverse patient population, PrEP prescribing rates were low, underscoring the urgent need for PrEP scale-up.
Literature
1.
go back to reference Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
2.
go back to reference Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed
3.
go back to reference Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
5.
go back to reference Hood JE, Buskin SE, Dombrowski JC, et al. Dramatic increase in preexposure prophylaxis use among MSM in Washington state. AIDS. 2016;30(3):515–9.PubMed Hood JE, Buskin SE, Dombrowski JC, et al. Dramatic increase in preexposure prophylaxis use among MSM in Washington state. AIDS. 2016;30(3):515–9.PubMed
6.
go back to reference Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.CrossRefPubMedPubMedCentral Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.CrossRefPubMedPubMedCentral
7.
go back to reference Montgomery MC, Oldenburg CE, Nunn AS, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE. 2016;11(6):e0157742.CrossRefPubMedPubMedCentral Montgomery MC, Oldenburg CE, Nunn AS, et al. Adherence to pre-exposure prophylaxis for HIV prevention in a clinical setting. PLoS ONE. 2016;11(6):e0157742.CrossRefPubMedPubMedCentral
10.
go back to reference Hanna DB, Felsen UR, Ginsberg MS, et al. Increased antiretroviral therapy use and virologic suppression in the bronx in the context of multiple HIV prevention strategies. AIDS Res Hum Retrovir. 2016;32(10–11):955–63.CrossRefPubMed Hanna DB, Felsen UR, Ginsberg MS, et al. Increased antiretroviral therapy use and virologic suppression in the bronx in the context of multiple HIV prevention strategies. AIDS Res Hum Retrovir. 2016;32(10–11):955–63.CrossRefPubMed
11.
go back to reference Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral
12.
go back to reference Chu C, Umanski G, Blank A, Grossberg R, Selwyn PA. HIV-infected patients and treatment outcomes: an equivalence study of community-located, primary care-based HIV treatment vs. hospital-based specialty care in the Bronx, New York. AIDS Care. 2010;22(12):1522–9.CrossRefPubMedPubMedCentral Chu C, Umanski G, Blank A, Grossberg R, Selwyn PA. HIV-infected patients and treatment outcomes: an equivalence study of community-located, primary care-based HIV treatment vs. hospital-based specialty care in the Bronx, New York. AIDS Care. 2010;22(12):1522–9.CrossRefPubMedPubMedCentral
13.
go back to reference Blackstock OJ, Moore BA, Berkenblit GV, et al. A cross-sectional online survey of HIV pre-exposure prophylaxis adoption among primary care physicians. J Gen Intern Med. 2016. doi:10.1007/s11606-016-3903-z.PubMed Blackstock OJ, Moore BA, Berkenblit GV, et al. A cross-sectional online survey of HIV pre-exposure prophylaxis adoption among primary care physicians. J Gen Intern Med. 2016. doi:10.​1007/​s11606-016-3903-z.PubMed
16.
go back to reference Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102–10.CrossRefPubMedPubMedCentral Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102–10.CrossRefPubMedPubMedCentral
17.
go back to reference Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. Transgender women in clinical trials of pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2016;72(Suppl 3):S226–9.CrossRefPubMedPubMedCentral Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB. Transgender women in clinical trials of pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2016;72(Suppl 3):S226–9.CrossRefPubMedPubMedCentral
20.
go back to reference Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American community survey. JMIR Public Health Surveill. 2016;2(1):e14.CrossRefPubMedPubMedCentral Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American community survey. JMIR Public Health Surveill. 2016;2(1):e14.CrossRefPubMedPubMedCentral
21.
go back to reference Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition-United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291–5.CrossRefPubMed Smith DK, Van Handel M, Wolitski RJ, et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition-United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(46):1291–5.CrossRefPubMed
Metadata
Title
Reaching Key Populations: PrEP Uptake in an Urban Health Care System in the Bronx, New York
Authors
Cedric H. Bien
Viraj V. Patel
Oni J. Blackstock
Uriel R. Felsen
Publication date
01-05-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1663-8

Other articles of this Issue 5/2017

AIDS and Behavior 5/2017 Go to the issue